Publications by authors named "S I Anjie"
Article Synopsis
- Infliximab and vedolizumab are common treatments for Crohn's disease (CD) and ulcerative colitis (UC), and this systematic review aimed to compare their effectiveness during maintenance therapy.
- The analysis included 13 randomized controlled trials (RCTs), focusing on clinical remission rates and mucosal healing in patients with moderate-to-severe CD or UC.
- Results indicated that subcutaneous infliximab 120 mg every two weeks provided the best odds for clinical remission and improved endoscopic outcomes compared to other regimens.
Subcutaneous vedolizumab has demonstrated efficacy as a maintenance therapy in inflammatory bowel disease (IBD). However, data on the extension of subcutaneous vedolizumab injection intervals are lacking. Here, we present the first real-world data on subcutaneous vedolizumab interval extension in IBD patients.
View Article and Find Full Text PDFWe present a Crohn's disease patient receiving high dose upadacitinib treatment with elevated CPK levels and myopathy, and provide the reader with practical tips on stopping and restarting upadacitinib, emphasizing the need for adequate monitoring.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to explore how to improve treatment effectiveness in inflammatory bowel disease (IBD) patients who develop antibodies against anti-TNF medications, which can lead to treatment failure.
- A total of 255 IBD patients were assessed, with various strategies applied upon detection of these anti-drug antibodies (ADAs), including conservative management, drug optimization, and switching therapies.
- The results showed that switching therapies significantly increased clinical remission rates from 19% to 69% over one year, and combining dose escalation of anti-TNF with immunomodulators was the quickest and most effective method to reduce ADAs.
Introduction: During the last decades, biologics have revolutionized the treatment of Crohn's disease and ulcerative colitis. Even though the inflammatory bowel disease (IBD) armamentarium is rapidly expanding with novel biologics, anti-tumor necrosis factor (TNF) antibodies remain the first-line biologic therapy in most areas of the world. However, anti-TNF therapy is not effective in all patients (primary non-response) and patients can lose effect over time (secondary loss of response).
View Article and Find Full Text PDF